Comparative Pharmacology
Head-to-head clinical analysis: TYCOLET versus TYLOX 325.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TYCOLET versus TYLOX 325.
TYCOLET vs TYLOX-325
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetaminophen: COX-1/COX-2 inhibitor in CNS; Paracetamol: analgesic and antipyretic via central inhibition of prostaglandin synthesis.
Acetaminophen and oxycodone combination. Acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis. Oxycodone is a mu-opioid receptor agonist, activating descending pain pathways and altering pain perception.
500-1000 mg orally or intravenously every 4-6 hours, maximum 4 g/day.
1-2 capsules (oxycodone 5-10 mg / acetaminophen 325-650 mg) orally every 4-6 hours as needed for pain; maximum 12 capsules per day.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours; prolonged in renal impairment (up to 12-24 hours in ESRD).
Acetaminophen: 2-3 hours (prolonged in hepatic impairment). Oxycodone: 3-5 hours (extended-release preparation); terminal half-life 4.5-5.5 hours. Clinical context: repeated dosing may lead to accumulation; half-life prolongation in elderly, renal or hepatic disease.
Renal: 70-80% unchanged; Biliary/fecal: 10-15% as metabolites.
Renal: acetaminophen metabolites (60-70% as glucuronide conjugate, 20-30% as sulfate conjugate, 5-10% as cysteine conjugate, 5% unchanged). Oxycodone: renal (primarily metabolites, <10% unchanged); biliary/fecal: minor (oxycodone metabolites).
Category C
Category C
Opioid analgesic combination
Opioid analgesic combination